| __timestamp | Biogen Inc. | Catalent, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1171036000 | 1229100000 |
| Thursday, January 1, 2015 | 1240400000 | 1215500000 |
| Friday, January 1, 2016 | 1478700000 | 1260500000 |
| Sunday, January 1, 2017 | 1630000000 | 1420800000 |
| Monday, January 1, 2018 | 1816300000 | 1710800000 |
| Tuesday, January 1, 2019 | 1955400000 | 1712900000 |
| Wednesday, January 1, 2020 | 1805200000 | 2111000000 |
| Friday, January 1, 2021 | 2109700000 | 2646000000 |
| Saturday, January 1, 2022 | 2278300000 | 3188000000 |
| Sunday, January 1, 2023 | 2533400000 | 3216000000 |
| Monday, January 1, 2024 | 0 | 3428000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. Over the past decade, Biogen Inc. and Catalent, Inc. have shown distinct trends in their cost of revenue. From 2014 to 2023, Biogen's cost of revenue increased by approximately 116%, peaking in 2023. Meanwhile, Catalent's expenses surged by nearly 162%, reflecting its aggressive expansion strategy. Notably, Catalent's costs surpassed Biogen's in 2020, maintaining a lead through 2023. This shift highlights Catalent's growing market presence. However, data for Biogen in 2024 is missing, leaving room for speculation on its future trajectory. As the pharmaceutical landscape continues to shift, these insights provide a window into the strategic financial maneuvers of two industry giants.
Takeda Pharmaceutical Company Limited vs Biogen Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Catalent, Inc.
Cost of Revenue: Key Insights for Biogen Inc. and Incyte Corporation
Cost of Revenue: Key Insights for Biogen Inc. and Viatris Inc.
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Catalent, Inc. and Alkermes plc's Expenses
Cost Insights: Breaking Down Catalent, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Cost of Revenue Trends: Catalent, Inc. vs Dyne Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Catalent, Inc. vs Galapagos NV
Analyzing Cost of Revenue: Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Catalent, Inc. vs Viridian Therapeutics, Inc.